JP2020515582A - 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート - Google Patents

腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート Download PDF

Info

Publication number
JP2020515582A
JP2020515582A JP2019553244A JP2019553244A JP2020515582A JP 2020515582 A JP2020515582 A JP 2020515582A JP 2019553244 A JP2019553244 A JP 2019553244A JP 2019553244 A JP2019553244 A JP 2019553244A JP 2020515582 A JP2020515582 A JP 2020515582A
Authority
JP
Japan
Prior art keywords
tumor
cancer
conjugate
host animal
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515582A5 (enExample
Inventor
イオンチョ・ラドスラヴォフ・ヴラホフ
クリストファー・ポール・リーモン
ロンウー・チィ
ニン・ゾウ
ケビン・ユー・ワン
アルバート・イー・フェルテン
ガース・エル・パラム
フェイ・ユウ
ハリ・クリシュナ・アール・サンタプラム
スペンサー・ジェイ・ハーン
ジョセフ・アナンド・レディ
インジュアン・ジェイ・ル
レロイ・ダブリュー・ホイーラー・ザ・セカンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Priority claimed from PCT/US2017/051662 external-priority patent/WO2018182776A1/en
Publication of JP2020515582A publication Critical patent/JP2020515582A/ja
Publication of JP2020515582A5 publication Critical patent/JP2020515582A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019553244A 2016-03-29 2017-09-14 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート Pending JP2020515582A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662314688P 2016-03-29 2016-03-29
US201662323282P 2016-04-15 2016-04-15
US201662396409P 2016-09-19 2016-09-19
PCT/US2017/024770 WO2017172930A1 (en) 2016-03-29 2017-03-29 Pbd conjugates for treating diseases
USPCT/US2017/024770 2017-03-29
PCT/US2017/051662 WO2018182776A1 (en) 2016-03-29 2017-09-14 Folate conjugate for use in targeting tumor associated macrophages

Publications (2)

Publication Number Publication Date
JP2020515582A true JP2020515582A (ja) 2020-05-28
JP2020515582A5 JP2020515582A5 (enExample) 2020-10-22

Family

ID=59965167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553244A Pending JP2020515582A (ja) 2016-03-29 2017-09-14 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート

Country Status (3)

Country Link
US (2) US20200323991A1 (enExample)
JP (1) JP2020515582A (enExample)
WO (1) WO2017172930A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
WO2018182776A1 (en) * 2016-03-29 2018-10-04 Endocyte, Inc. Folate conjugate for use in targeting tumor associated macrophages
CN109689111B (zh) * 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
EP3717021A1 (en) * 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN109824622B (zh) * 2019-02-27 2022-12-30 中国科学技术大学 一类细胞内形成纳米结构杀死癌细胞的前体药物及其制法
CN120535564B (zh) * 2025-07-24 2025-09-23 杭州诺泰诺和生物医药科技有限公司 一种含有Sar linker的多肽的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526577A (ja) * 2010-05-19 2013-06-24 エンドサイト，インコーポレイテッド 葉酸を標的にする薬剤用の改善されたプロセス
WO2016085967A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) * 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112708A1 (en) * 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
EP2908818A4 (en) * 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
EA032986B1 (ru) * 2012-12-21 2019-08-30 Медимьюн Лимитед Пирролобензодиазепины
SG11201701623UA (en) * 2014-09-12 2017-03-30 Genentech Inc Anti-her2 antibodies and immunoconjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526577A (ja) * 2010-05-19 2013-06-24 エンドサイト，インコーポレイテッド 葉酸を標的にする薬剤用の改善されたプロセス
WO2016085967A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) * 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER P. LEAMON, ET AL.: ""Folate-Vinca Alkaloid Conjugates for Cancer Therapy: A Structure-Activity Relationship"", BIOCONJUGATE CHEMISTRY, vol. 25, no. 3, JPN6021027746, 2014, pages 560 - 568, ISSN: 0004550065 *
SHIKHAR TYAGI, ET AL.: ""Folate conjugates: A boon in the anti-cancer therapeutics"", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 7, no. 11, JPN6021027745, 2016, pages 4278 - 4303, ISSN: 0004550066 *

Also Published As

Publication number Publication date
WO2017172930A1 (en) 2017-10-05
US20200323991A1 (en) 2020-10-15
US20200038514A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
JP6568093B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP2020515582A (ja) 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート
US20190343852A1 (en) Compositions and methods for inhibiting arginase activity
JPWO2020130125A1 (ja) 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN106470696B (zh) 用于治疗癌症的药物组合
US20150246033A1 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
JP2022516090A (ja) 癌の治療において使用するためのｃｓｆ１ｒ阻害剤
JP2021501145A (ja) 血液学的障害を治療するための化合物および組成物
JP2006508981A (ja) 癌を治療するためのインドリノンと化学療法剤との組み合わせ投与
US20230321042A1 (en) Combination therapy
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
CA3029596A1 (en) Methods for treating cancer
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
WO2018182776A1 (en) Folate conjugate for use in targeting tumor associated macrophages
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
TWI698238B (zh) Ｅｚｈ２抑制劑組合治療
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
CN117500803A (zh) 用于治疗具egfr突变的癌症的氨基取代杂环

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220301